标题
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
作者
关键词
-
出版物
Cells
Volume 9, Issue 2, Pages 287
出版商
MDPI AG
发表日期
2020-01-25
DOI
10.3390/cells9020287
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Natural history of multiple myeloma with de novo del(17p)
- (2019) Arjun Lakshman et al. Blood Cancer Journal
- Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition
- (2019) Ahmed Diab et al. MOLECULAR CANCER RESEARCH
- High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
- (2019) Anjan Thakurta et al. BLOOD
- Hierarchy of mono- and bi-allelic TP53 alterations in Multiple Myeloma cell fitness
- (2019) Umair Munawar et al. BLOOD
- Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival
- (2019) Crystal A. Tonnessen-Murray et al. JOURNAL OF CELL BIOLOGY
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
- (2019) Steffen Boettcher et al. SCIENCE
- Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
- (2019) Lawrence A. Donehower et al. Cell Reports
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
- (2018) Brian A. Walker et al. BLOOD
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
- (2018) Brian A. Walker et al. LEUKEMIA
- Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
- (2018) Christopher D. Wiley et al. Scientific Reports
- Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function
- (2018) Julie A. Barta et al. MOLECULAR CANCER RESEARCH
- Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2
- (2018) Byung-Kwon Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Towards personalized treatment in multiple myeloma based on molecular characteristics
- (2018) Charlotte Pawlyn et al. BLOOD
- Subclonal TP53 copy number is associated with prognosis in multiple myeloma
- (2018) Vallari Shah et al. BLOOD
- TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database
- (2018) Victor D. Li et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
- (2018) Yujing Li et al. Nature Communications
- Essential role for centromeric factors following p53 loss and oncogenic transformation
- (2017) Dan Filipescu et al. GENES & DEVELOPMENT
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- (2017) Sharmilan Thanendrarajan et al. HAEMATOLOGICA
- Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
- (2017) V Shah et al. LEUKEMIA
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
- (2017) M Chin et al. Blood Cancer Journal
- Exploiting the p53 Pathway for Therapy
- (2017) Chit Fang Cheok et al. Cold Spring Harbor Perspectives in Medicine
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- (2017) Sharmilan Thanendrarajan et al. HAEMATOLOGICA
- Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant
- (2016) Sameh Gaballa et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
- (2016) Alice Soragni et al. CANCER CELL
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
- (2016) Liacine Bouaoun et al. HUMAN MUTATION
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
- (2016) Yu Liu et al. NATURE
- An open-label phase I dose-finding study of APR-246 in hematological malignancies
- (2016) S Deneberg et al. Blood Cancer Journal
- Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
- (2016) Perry Tal et al. Oncotarget
- TP53 mutations, expression and interaction networks in human cancers
- (2016) Xiaosheng Wang et al. Oncotarget
- The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
- (2016) E. K. Law et al. Science Advances
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
- (2015) G. An et al. CLINICAL CANCER RESEARCH
- Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer
- (2015) Adam R. Blanden et al. DRUG DISCOVERY TODAY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 loss creates therapeutic vulnerability in colorectal cancer
- (2015) Yunhua Liu et al. NATURE
- SIFT missense predictions for genomes
- (2015) Robert Vaser et al. Nature Protocols
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
- (2015) Evrim Gurpinar et al. TRENDS IN CELL BIOLOGY
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
- (2015) Brian A. Walker et al. Nature Communications
- Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability
- (2015) Ana B. Herrero et al. PLoS One
- Cyclotherapy: opening a therapeutic window in cancer treatment
- (2015) Ingeborg M.M. van Leeuwen Oncotarget
- Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells
- (2014) William N Pappano et al. BMC CANCER
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
- (2014) R. Moser et al. CLINICAL CANCER RESEARCH
- The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk
- (2014) Christine M. Eischen et al. HUMAN MUTATION
- p53 haploinsufficiency and functional abnormalities in multiple myeloma
- (2014) P J Teoh et al. LEUKEMIA
- Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure
- (2014) Julien Ablain et al. NATURE MEDICINE
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- (2014) E. C. de Bruin et al. SCIENCE
- A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage
- (2014) Vincent Caval et al. Nature Communications
- Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations
- (2014) Jie Xu et al. Scientific Reports
- APOBEC-Mediated Cytosine Deamination Links PIK3CA Helical Domain Mutations to Human Papillomavirus-Driven Tumor Development
- (2014) Stephen Henderson et al. Cell Reports
- Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
- (2014) Anieta M. Sieuwerts et al. Hormones & Cancer
- Identification of potential synthetic lethal genes to p53 using a computational biology approach
- (2013) Xiaosheng Wang et al. BMC Medical Genomics
- p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy
- (2013) B Rao et al. BRITISH JOURNAL OF CANCER
- Local Depletion of DNA Methylation Identifies a Repressive p53 Regulatory Region in theNEK2Promoter
- (2013) Nancy H. Nabilsi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Emerging landscape of oncogenic signatures across human cancers
- (2013) Giovanni Ciriello et al. NATURE GENETICS
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
- (2013) Hyo Jeong Kang et al. PLoS One
- A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
- (2013) Sandra Morandell et al. Cell Reports
- p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
- (2012) Mei-Hsi Chen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
- (2012) Ming Kei Lee et al. CANCER CELL
- Allele-Specific p53 Mutant Reactivation
- (2012) Xin Yu et al. CANCER CELL
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations
- (2012) Tobias Rausch et al. CELL
- Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
- (2012) S. Yachida et al. CLINICAL CANCER RESEARCH
- Centrosomes, chromosome instability (CIN) and aneuploidy
- (2012) Benjamin D Vitre et al. CURRENT OPINION IN CELL BIOLOGY
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
- (2012) Bernard Leroy et al. NUCLEIC ACIDS RESEARCH
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
- (2011) P. Neri et al. BLOOD
- APOBEC3A can activate the DNA damage response and cause cell-cycle arrest
- (2011) Sébastien Landry et al. EMBO REPORTS
- The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
- (2011) Kevin D. Boyd et al. GENES CHROMOSOMES & CANCER
- Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
- (2011) R. Vermeij et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Predicting the functional impact of protein mutations: application to cancer genomics
- (2011) Boris Reva et al. NUCLEIC ACIDS RESEARCH
- A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
- (2010) B. A. Walker et al. BLOOD
- Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma
- (2010) Manujendra N. Saha et al. CANCER BIOLOGY & THERAPY
- MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
- (2010) Manujendra N. Saha et al. CANCER BIOLOGY & THERAPY
- Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy
- (2010) Meng Ling Choong et al. CELL CYCLE
- p53-dependent repression of polo-like kinase-1 (PLK1)
- (2010) Lynsey McKenzie et al. CELL CYCLE
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
- (2010) L. Lode et al. HAEMATOLOGICA
- Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains
- (2010) Hong Chang et al. LEUKEMIA RESEARCH
- Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3
- (2010) Amy Baldwin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells
- (2009) H Hasegawa et al. LEUKEMIA
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
- (2009) S. Sur et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now